Klein, E.-M.; Tichy, D.; Salwender, H.J.; Mai, E.K.; Duerig, J.; Weisel, K.C.; Benner, A.; Bertsch, U.; Akhavanpoor, M.; Besemer, B.;
et al. Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial. Cancers 2021, 13, 4856.
https://doi.org/10.3390/cancers13194856
AMA Style
Klein E-M, Tichy D, Salwender HJ, Mai EK, Duerig J, Weisel KC, Benner A, Bertsch U, Akhavanpoor M, Besemer B,
et al. Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial. Cancers. 2021; 13(19):4856.
https://doi.org/10.3390/cancers13194856
Chicago/Turabian Style
Klein, Eva-Maria, Diana Tichy, Hans J. Salwender, Elias K. Mai, Jan Duerig, Katja C. Weisel, Axel Benner, Uta Bertsch, Mabast Akhavanpoor, Britta Besemer,
and et al. 2021. "Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial" Cancers 13, no. 19: 4856.
https://doi.org/10.3390/cancers13194856
APA Style
Klein, E.-M., Tichy, D., Salwender, H. J., Mai, E. K., Duerig, J., Weisel, K. C., Benner, A., Bertsch, U., Akhavanpoor, M., Besemer, B., Munder, M., Lindemann, H.-W., Hose, D., Seckinger, A., Luntz, S., Jauch, A., Elmaagacli, A., Fuhrmann, S., Brossart, P.,
... on behalf of the German-Speaking Myeloma Multicenter Group (GMMG).
(2021). Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial. Cancers, 13(19), 4856.
https://doi.org/10.3390/cancers13194856
